Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Morphine sulfate + oxycodone hydrochloride is a combination of two opioid analgesics used for the management of moderate to severe pain when alternative treatment options are inadequate. Both components act primarily as agonists at the mu-opioid receptor in the central nervous system, resulting in analgesia, sedation, and euphoria. Morphine is a naturally occurring opiate derived from the poppy plant and acts mainly as a mu-opioid receptor agonist. Oxycodone is a semisynthetic opioid derived from thebaine and also acts predominantly on mu-opioid receptors but has some activity at kappa and delta receptors as well[1][3][5]. The combination may be considered in certain clinical scenarios to optimize pain control; however, evidence suggests that their coadministration does not produce synergistic antinociceptive effects in healthy humans[1]. Both drugs carry risks of dependence, tolerance, respiratory depression, constipation, and other opioid-related adverse effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on morphine sulfate + oxycodone hydrochloride.